Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;36(7):961-5.
doi: 10.1007/s00296-016-3467-6. Epub 2016 Mar 23.

Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome

Affiliations

Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome

Isha Saini et al. Rheumatol Int. 2016 Jul.

Abstract

The aim was to retrospectively estimate the prevalence of calcinosis in patients with juvenile dermatomyositis (JDM) and to identify risk factors associated with development of calcinosis in these patients. Retrospective chart review of 39 children diagnosed with JDM between 2004 and 2015 in a tertiary care hospital was done. Patients were divided into two groups, depending on the presence or absence of calcinosis, and the two groups were compared with respect to demographic, clinical, laboratory and therapeutic characteristics. Calcinosis developed in nine (23.1 %) patients. Delay in diagnosis and initiation of treatment, prolonged duration of disease, the presence of joint contractures and cardiac involvement were significantly associated with increased frequency of calcinosis. Six out of nine (66.7 %) patients with calcinosis received alendronate therapy, out of which four showed partial reduction in calcinosis. In one case, surgical removal of tumorous clumps was done. Calcinosis remains a common complication of JDM. We found an association between calcinosis and delay in diagnosis and initiation of treatment, prolonged duration of disease and cardiac involvement. Our study suggests that alendronate may be beneficial in management of calcinosis of JDM.

Keywords: Alendronate; Calcinosis; Juvenile dermatomyositis; Risk factors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Rheumatol. 2010 Jan;37(1):194 - PubMed
    1. Clin Rheum Dis. 1984 Apr;10(1):95-115 - PubMed
    1. N Engl J Med. 1975 Feb 13;292(7):344-7 - PubMed
    1. J Bone Miner Res. 1998 Nov;13(11):1668-78 - PubMed
    1. Rheum Dis Clin North Am. 2002 Nov;28(4):833-57 - PubMed

MeSH terms

LinkOut - more resources